INTRODUCTION
Arteriosclerosis is a pathologic condition characterized by fibrointimal thickening of the arteries; it leads to a progressive form of vascular obliteration and dysfunction of various organs. Arteriosclerosis is also a component of a more general arterial disease called "atherosclerosis", which describes a heterogeneous disease with a continuum between pure arteriosclerosis and fibrolipidic plaques (atheroma) (1) (2) (3) .
Arteriosclerosis is recognized as a primary cause of end-stage renal disease (4) and loss of kidney (5, 6) and heart transplants (7) . Arteriosclerosis is also part of a more general burden of cardiovascular disease that is responsible for heart failure and cerebral strokes, leading to increased morbidity and mortality (8) (9) (10) .
The prevailing hypothesis holds that the main contributors to arteriosclerosis include conventional cardiovascular risk factors such as hypertension, tobacco consumption and aging (8) . However, it has been suggested that immune and inflammatory processes play a role in arteriosclerosis and more generally in atherosclerosis, as supported by animal experimental data and clinical observations in autoimmune diseases (2, 11, 12, (13) (14) (15) (16) . Animal models are limited by the fact that they do not recapitulate the human pathophysiology of immune-mediated vascular injury (17, 18, 19) , while human studies lack access to patient arteries for histopathologic analysis and exhibit slow disease progression. As a consequence, we have an incomplete understanding of the respective contributions of non-immune and immune factors in arteriosclerosis and their local (organ failure) and more general consequences (patient death and cardiovascular events). Solid-organ transplant offers the unique opportunity to address the general condition of arteriosclerosis disease by using kidney transplantation as a human prototype for the antibody-dependent immune response that co-exists with traditional risk factors.
In view of the profound interactions between the immune system and the vessels that characterize solid organ transplantation (2, (20) (21) (22) (23) (24) (25) , we used a population-based approach to assess the determinants of premature arteriosclerosis in a cohort of extensively phenotyped kidney transplant patients. While observations have suggested an association between antibodies and local allograft arteriosclerosis (5, 26) , the extent to which antibodies are independent risk factors in premature arteriosclerosis and occurrence of MACE, beyond traditional risk factors, is still unknown.
The aim of the present population-based study was to use a model of premature vascular injury to evaluate the respective contributions of immune and non-immune factors and to integrate these factors into the more general process of arteriosclerosis disease. We used a multidisciplinary approach in a large prospective cohort of kidney recipients. Patients were assessed for traditional cardiovascular risk factors as well as circulating anti-HLA antibodies and their properties (specificity, HLA class, strength and complement-binding capacity) and underwent prospective kidney allograft biopsies to assess arteriosclerotic lesions and markers of endothelial activation, endarteritis and local complement deposition. We assessed the determinants of local severe arteriosclerosis (in allografts) and the occurrence of MACE.
METHODS

Multidisciplinary network.
This study involved the Paris Translational Research Center for Organ Transplantation, which is a multidisciplinary collaborative research project with the aim of advancing basic knowledge regarding the determinants of vascular diseases. This network includes experts in the fields of cardiology, nephrology, transplant immunology, basic science, histopathology and epidemiology.
Study population.
This population-based study included consecutive patients who underwent kidney transplantation at Necker Hospital (Paris, France) between Jan 1, 2004, and Jan 1, 2010 (n=1012). We included all patients who underwent a systematic evaluation of arteriosclerosis upon kidney biopsy at 1 year post-transplantation (n=744). We excluded 144 patients who did not reach the 1-year follow-up (graft failure n=53, patient death n=26) or who were lost to follow-up in the first year post-transplant (n=65). Patients who did not undergo a screening biopsy (contraindication, refusal, or not conducted) or for whom the screening biopsy was performed but was not adequate according to the international classification for kidney allograft histopathology were also excluded from the analysis (n=124). We also used an additional independent validation sample of 321 kidney recipients from Saint-Louis Hospital (Paris, France; see methods section, "Independent validation cohort"). The study was approved by the Institutional Review Boards of Necker Hospital and Saint-Louis Hospital.
Data collection.
Clinical data were obtained from a prospective database, Données Informatiques Validées en Transplantation (DIVAT clinical prospective cohort, official website: www.divat.fr), in which data were entered at specific points for each patient (at day 0, 6 months and 1 year post-transplantation); follow-up was updated annually thereafter (27). For the DIVAT database, all data were prospectively entered by research assistants under the supervision of transplant clinicians, and the database underwent an annual external audit for data accuracy. For each patient, follow-up data after 1 year were entered based on a complete review of the medical charts and the collection of clinical events, including cardiovascular complications. Data were retrieved from the database on April 15, 2012.
We performed an extensive evaluation of potential non-immune (classical) and immune (antibody-related) risk factors that might be associated with arteriosclerosis. We analyzed the following data: i) donor cardiovascular profile, including age at donation, sex, cerebrovascular cause of death (including ischemia and/or hemorrhagic cerebral stroke), the presence of hypertension, diabetes mellitus, or hypercholesterolemia, tobacco consumption, and renal function at donation; ii) recipient cardiovascular profile at the time of transplantation, including age, sex, body mass index, hypertension, diabetes mellitus, hypercholesterolemia, tobacco consumption, past history of MACE (myocardial infarction, unstable angina, revascularization, cerebral stroke and severe peripheral arterial disease that required revascularization), and the use of calcineurin inhibitors (CNIs) and corticosteroid dose; iii) recipient cardiovascular profile assessed at 6 months post-transplant, including blood pressure, diabetes mellitus, LDL levels, anti-hypertensive therapy, and the use of antiaggregant or statin therapy; iv) immunological parameters (HLA mismatch, rejection and the presence of circulating anti-HLA donor-specific antibodies (DSA) post-transplant); and v) transplant characteristics (cold ischemia time, graft rank and delayed graft function).
Definition of arteriosclerosis and allograft injury phenotype.
The severity of allograft arteriosclerosis and injury phenotypes were defined on the basis of allograft biopsies taken at 1 year post-transplant in all 744 included patients. Allograft arteriosclerosis was defined and graded based on the criteria established by the international Banff classification on allograft pathology (28, 29) and was assessed by trained pathologists (JPDVH, PB) who were blinded to the clinical information.
The Banff arteriosclerosis score reflects the degree of narrowing of the luminal area in the worst involved artery in the biopsy as follows: cv0 -no chronic vascular changes; cv1 -vascular luminal narrowing of up to 25% via fibrointimal arterial thickening; cv2 -vascular luminal narrowing of 26 to 50%; and cv3 -vascular narrowing of up to 50% (30). We used the Banff classification to separate minimal arteriosclerosis (Banff scores of 0 and 1) from severe arteriosclerosis (Banff scores of 2 and 3) (28-30).
In addition to the degree of arteriosclerosis, we assessed the presence of microcirculatory inflammation, arteritis, arterial hyalinosis and atrophic scarring in all biopsies (28, 29). We also evaluated the deposition of complement in the graft capillaries and arteries using complement split product C4d immunohistochemical staining on paraffin sections with a human polyclonal antibody (Biomedica). We recorded biopsy-proven acute rejection, as defined according to the international classification (31), during the first year post-transplant.
Detection and characterization of antibodies against donor-specific HLA molecules. All patients included in the present study were screened for the presence of circulating anti-HLA antibodies in serum collected at 6 months post-transplant. In addition, patients with evidence of acute allograft rejection were tested for circulating anti-HLA antibodies at the time of acute rejection. Antibodies against the HLA-A, HLA-B, HLA-Cw, HLA-DR, HLA-DQ, and HLA-DP epitopes were tested using singleantigen flow bead assays (One Lambda, Inc., Canoga Park, CA, USA) on a Luminex platform, as previously described (32, 33). All beads with a normalized mean fluorescence intensity (MFI) of greater than 500 were considered positive. In patients with multiple anti-HLA DSA, the immunodominant anti-HLA DSA (the one with the highest MFI) was selected for analysis. HLA typing of the recipients was performed via molecular biology (Innolipa HLA typing kit, Innogenetics, Belgium). For all kidney transplant donors, tissue typing was initially performed using the microlymphocytotoxicity technique with One Lambda Inc. tissue typing trays at transplantation and was confirmed by molecular biology.
Serum samples from patients with circulating donor-specific anti-HLA antibodies were analyzed in a blinded fashion for the presence of C1q-binding donor-specific anti-HLA antibodies using single-antigen flow bead assays according to the manufacturer's protocol (C1qScreenTM, One Lambda) (33).
Outcome parameters.
The outcomes measured in this study were time to graft loss, patient death and time to the development of MACE. Kidney allograft loss was defined by a return to dialysis, while MACE included the following complications: acute coronary syndrome (myocardial infarction, unstable angina), stroke, severe peripheral arterial disease and death from cardiovascular causes, including sudden death.
Independent validation cohort.
The external validation population included 321 consecutive kidney transplant recipients who had been transplanted at Saint-Louis Hospital. Kidney transplants were performed between Jan 1, 2006, and Jan 1, 2010. Data from Saint-Louis Hospital were collected from the French National Registry Agency's (Agence de la Biomédecine) Cristal database (official website: https://www.sipg.sante.fr/portail/) (34). Data were retrieved from the database on April 15, 2012. The same inclusion criteria as were used for the principal cohort (Necker hospital) were applied to the validation cohort; these included the performance of a protocol allograft biopsy at 1 year post-transplant and screening for circulating antibodies after transplantation.
Statistical analysis.
Continuous variables are described in terms of the mean and standard deviation (SD) values. We compared the means and proportions using Student's t-test and the chi-square test (or Fisher's exact test if appropriate).
First, within each group of potential risk factors, including the recipient cardiovascular profile, the donor cardiovascular profile, the transplant characteristics and the post-transplant immunological profile, we assessed the determinants of severe allograft arteriosclerosis at 1 year post-transplant. In the main analyses, severe allograft arteriosclerosis was constructed according to the cv score as a binary variable (2-3 -severe vs. 0-1 -minimal) to allow the use of a simple logistic regression analysis to identify the determinants of arteriosclerosis. Two sensitivity analyses were further conducted: (1) using the arteriosclerosis score in 4 categories (grade 0, 1, 2 and 3) and performing a multinomial logistic regression analysis using the grade cv0 score as the reference category; and (2) using the arteriosclerosis grade as a continuous (ordinal) variable and constructing a generalized linear model. Second, we determined whether severe antibody-associated arteriosclerosis was associated with long-term allograft loss and the future development of cardiovascular events.
The graft survival and patient survival analyses were performed for a maximum follow-up period of 7 years from the time of transplantation. Graft survival, patient survival and the occurrence of MACE were plotted on Kaplan-Meier curves according to the severity of arteriosclerosis and the presence of anti-HLA antibodies and were compared using the log-rank test. Last, we assessed the determinants of MACE in a Cox proportional hazards model.
For the logistic, linear and Cox regression models, we first performed univariate analysis. The p-value threshold of 0.10 for entering variable in the multivariate model was corrected using the Bonferroni correction method (0.1/31=0.003). Then, significant risk factors were entered in a single multivariate model using backward stepwise elimination.
RESULTS
Baseline characteristics of the study population. Table 1 summarizes the recipient and donor baseline profiles and the transplant characteristics in the overall population. The mean age of the 744 recipients was 47.8±12.9 years. A total of 429 (58%) recipients were male, 603 (81%) recipients had hypertension, 83 (11%) recipients had diabetes mellitus, 161 (22%) recipients had hypercholesterolemia, and 108 (15%) recipients presented with major cardiovascular events prior to transplantation. A total of 276 (37%) recipients were active or past smokers at the time of transplantation. The mean donor age was 50.6±15.9 years. A total of 407 (55%) donors were male. The prevalence rates of hypertension, diabetes mellitus and hypercholesterolemia in the donors were 23%, 4% and 7%, respectively. A total of 203 (38%) donors were active or past smokers at the time of donation.
Two distinct populations were identified according to the arteriosclerotic allograft lesions identified at 1 year post-transplantation: 1) kidney transplant recipients with minimal arteriosclerosis (0 to 25% arterial luminal narrowing) (n=494, 66.4%); and 2) kidney transplant recipients with severe arteriosclerosis (>25% arterial luminal narrowing) (n=250, 33.6%). Compared with the patients with minimal arteriosclerosis, the patients with severe arteriosclerosis were significantly older (45.4±12.5 vs. 52.4±12.5 years, p<0.0001), received allografts from older donors (46.9±15.8 vs. 57.8±13.5 years, p<0.0001), and were more likely to have received allografts from donors who died from cerebrovascular disease (50% vs. 64%, p<0.001, Table 1 ).
Determinants of severe arteriosclerosis.
Among the immune and non-immune parameters tested, the following factors were significantly associated with severe arteriosclerosis at 1 year post-transplantation in the univariate analysis: 1) recipient cardiovascular parameters at the time of transplantation (day 0) -age at transplantation (p<0.0001); 2) donor cardiovascular parameters -age (p<0.0001), hypertension (p<0.0001), diabetes mellitus (p<0.0001), hypercholesterolemia (p=0.0014), and donor death from cerebrovascular disease (p<0.0001); 3) transplant parameters -cold ischemia time (p<0.0001); 4) post-transplant recipient cardiovascular parameters (assessed at 6 months post-transplant in all patients) -systolic blood pressure (p=0.0007) and hypertension requiring antihypertensive therapy (p<0.0001); and 5) immunological and functional parameters -presence of circulating donor-specific antibodies (p<0.0001) and kidney function (p<0.0001). Associations with male donor gender (p=0.0102), graft rank (p=0.0317), recipient diabetes mellitus post-transplant (p=0.0254) and recipient blood LDL concentration post-transplant (p=0.0063) were above the threshold limits for p values of less than 0.003 (Table 2A ).
In the multivariate logistic regression model (Table 2B) , factors independently associated with severe arteriosclerosis at 1 year post-transplantation were donor age (per year increment, OR 1.05; 95% CI=1.03-1.06, p<0.0001), donor diabetes (OR 3.56; 95% CI=1.5-8.6, p=0.0046), allograft cold ischemia time per 1-hour increment, OR 1.0004 95% CI=1.000-1.001, p=0.0121), post-transplant recipient hypertension requiring antihypertensive therapy (OR 2.17; 95% CI=1.06-4.42, p=0.033), and the presence of circulating donor-specific antibodies (DSA) (OR 2.9; 95% CI=1.96-4.3, p<0.0001).
Finally, we defined the characteristics of the immunodominant circulating DSA and allograft injury phenotypes according to arteriosclerosis scores (Table 3) . We found that patients with increasing arteriosclerosis scores had higher circulating DSA MFI levels (p=0.0243), a higher prevalence of complement-binding DSA (p<0.0001), increased allograft endothelial activation (microcirculation inflammation, p<0.0001), and increased complement fraction C4d deposition in capillaries (p=0.011).
Phenotype of antibody-associated severe arteriosclerosis.
The histopathology of the 744 allograft biopsies taken at 1 year post-transplant revealed that patients with severe antibody-associated arteriosclerosis exhibited a distinct phenotype compared to patients with severe arteriosclerosis without antibodies and patients with minimal arteriosclerosis. The pathology in patients with severe antibody-associated atherosclerosis was characterized by i) increased microcirculatory inflammation (75% vs. 18% and 21%, respectively, p<0.0001), ii) a higher rate of complement fraction C4d deposition in allograft capillaries (35% vs. 7% and 8%, respectively, p<0.0001) and iii) a higher rate of arterial intimal inflammation (5% vs. 2% and 1%, respectively, p=0.023, Figure 1A ). Figure 1B depicts the phenotype of antibody-associated arteriosclerosis, demonstrating severe fibrointimal arterial narrowing (Panel A), complement fraction C4d deposition in the arterial intima (Panel B), endothelial activation (microcirculation inflammation, Panel C) and C4d deposition in capillaries (Panel D). The distribution of DSA HLA class in patients with antibody-associated arteriosclerosis was class I in 21/91 patients (23%), class II in 42/91 patients (46%) and class I+II in 28/91 patients (31%). The mean MFI level of the immunodominant DSA was 5091±465, and these patients were more likely to have preformed persisting DSA (64/91, 70%) than de novo DSA (27/91, 30%). Of the 91 patients with antibody-associated severe arteriosclerosis, 34 (37%) exhibited C1q binding capacity.
Outcome of antibody-associated severe arteriosclerosis.
We investigated the long-term consequences of severe antibody-associated arteriosclerosis.
Patients and allograft survival. Figure 2 shows kidney allograft (A) and patient (B) survival. The 3-and 7-year graft survival rates were, respectively, 93.2% and 76.9% in the group of patients with severe antibody-associated arteriosclerosis, 97.5% and 92.7% in the group with severe arteriosclerosis without antibodies, and 97.9% and 93.1% in patients with minimal arteriosclerosis (log rank, p=0.001).
The 3-and 7-year patient survival rates were, respectively, 95.6% and 80.8% in the group of patients with antibody-associated severe arteriosclerosis, 96.9% and 93.2% in the group with severe arteriosclerosis without antibodies, and 98.4% and 93.4% in the group of patients with minimal arteriosclerosis (log-rank p=0.001).
Occurrence of MACE.
A total of 72 (10%) patients presented with episodes of MACE after 1 year post-transplant, including 29 (40%) patients with acute coronary syndrome, 7 (10%) patients with stroke, 29 (40%) patients with severe peripheral arterial disease and 7 (10%) deaths from fatal cardiovascular causes. The median time to the occurrence of MACE was 2.5 years (IQR 0.99-3.45). The risk of MACE significantly differed between patients with minimal arteriosclerosis, patients with severe arteriosclerosis without antibodies and patients with severe antibody-associated arteriosclerosis (Figure 3) . Furthermore, two-by-two comparisons indicated that patients with severe antibody-associated arteriosclerosis exhibited a 2.5-fold increased risk of MACE (95% CI=1.3-4.9, p=0.005) compared with patients with severe arteriosclerosis without antibodies and a 4.1-fold increased risk of MACE (95% CI=2.4-7.2, p<0.0001) compared with patients with minimal arteriosclerosis.
Determinants of MACE.
In the univariate Cox model, the following traditional factors were significantly associated with an increased risk of MACE: recipient age (p<0.0001), past history of MACE (p=0.0002), recipient diabetes mellitus post-transplant (p=0.0009) and kidney function (p=0.0018). In addition, the cold ischemia time (p<0.0001) and presence of circulating DSA (p=0.0002) were associated with the risk of MACE (Online Table I ). In the multivariate Cox model (Table 4) , factors independently associated with the occurrence of MACE were recipient age (per year increment, HR 1.029; 95% CI=1.007-1.052, p=0.0092), recipient diabetes mellitus post-transplant (HR 1.767; 95% CI=1.067-2.926, p=0.0269), allograft cold ischemia time (per 1-hour increment, HR 1.037 95% CI=1.011-1.063, p=0.0050), past history of MACE (HR 1.924; 95% CI=1.117-3.313, p=0.0184) and the presence of circulating DSA (HR 2.424; 95% CI=1.490-3.945, p=0.0004).
Among the patients with circulating DSA, we defined the characteristics of the immunodominant DSA according to the occurrence of MACE (Online Table II ). We found that compared to patients without MACE, the patients with MACE had higher circulating DSA MFI levels (3903±231 vs. 6307±895, respectively; p=0.0035) and a higher prevalence of complement-binding DSA (20% vs. 62%, respectively; p<0.0001).
Acute coronary syndrome (p=0.007) and death from cardiovascular causes (p=0.001) were overrepresented in the patients with DSA compared to the patients without, while the occurrence of peripheral arterial disease and stroke remained similar between DSA-positive and negative patients.
Sensitivity analysis.
First, when using other thresholds to define arteriosclerosis at 1 year, including contrasting each grade from 1 to 3 against grade 0 in a multinomial logistic regression (Online Table III ) or using the cv score as a continuous variable in the generalized linear model (Online Table IV) , we found consistent associations between circulating DSA and the severity of arteriosclerosis. We also showed that when the preimplantation biopsy evaluation of arteriosclerosis was included, circulating donor-specific anti-HLA antibodies remained strongly and independently associated with severe allograft arteriosclerosis at 1 year posttransplant (OR 3.058; 95% CI=1.69-5.52, p=0.0002), as shown in Online Table V. Second, when the level of renal function (assessed by glomerular filtration rate [GFR]) was included in the final multivariate model, the independent determinants of arteriosclerosis and MACE remained unchanged.
Third, when peripheral arterial diseases were excluded from the MACE definition, the set of risk factors identified in the multivariate Cox model of the determinants of MACE remained unchanged, with circulating DSA being strongly associated with increased risk of MACE, independent of traditional risk factors (HR 3.175; 95% CI=1.726-5.843, p=0.0002), as shown in Online Table VI. Forth, when we included the degree of allograft arteriosclerosis in the Cox model of the determinants of MACE, the presence of circulating anti-HLA DSA remained strongly associated with the occurrence of MACE (HR=2.3, p=0.0014). The degree of allograft arteriosclerosis was not associated with the occurrence of MACE (p=0.16).
External validation.
The external validation cohort was composed of 321 patients whose baseline characteristics (compared to those of the principal cohort) are presented in Online Table VII. The multivariate logistic regression model confirmed the independent association of circulating anti-HLA DSA with severe arteriosclerosis at 1 year post-transplant (Online Table VIII ).
The analysis of the allograft biopsies performed at 1 year confirmed that patients with antibodyassociated severe arteriosclerosis had significantly increased microcirculatory inflammation (p<0.0001), complement fraction C4d deposition in the allograft capillaries (p=0.032) and arteritis lesions (p=0.001) (Online Table IX ).
The Kaplan-Meier survival analysis confirmed that patients with severe antibody-associated arteriosclerosis had decreased patient and allograft survival compared to the group of patients with severe arteriosclerosis without antibodies and minimal arteriosclerosis, respectively (p=0.009 and p<0.001, respectively; see Online Figure I ).
DISCUSSION
Using an integrated and population-based approach that combined contemporary immunological and histopathological techniques, we demonstrated the major role of circulating anti-HLA antibodies in the development of severe allograft arteriosclerosis, independent of traditional cardiovascular risk factors and renal function. Antibody-associated severe arteriosclerosis has a distinct phenotype that is characterized by endothelial activation, endarteritis and local complement deposition. We showed that the amount of circulating anti-HLA antibodies, together with their complement-binding capacity, are strongly correlated with the severity of arteriosclerosis. Finally, we demonstrated that circulating anti-HLA antibodies is a determinant of MACE independently of traditional cardiovascular risk factors. The recognition of an immune component of arterial disease (antibody-associated severe arteriosclerosis) identifies a local disease with general cardiovascular consequences and increased mortality.
Kidney transplantation provides a unique opportunity to address the unmet need of defining the respective roles of non-immune and immune factors in the development of premature arteriosclerosis. First, kidney transplantation is a prototypic antibody-dependent alloimmune response, with primary microcirculatory and macrocirculatory endothelial injuries that can be characterized and precisely phenotyped using allograft biopsies (25, 26, 35). Second, traditional cardiovascular risk factors are overrepresented in kidney transplant recipients, in whom cardiovascular disease represents the main cause of death (36, 37). Kidney transplantation thus provides the possibility of using this population as a prototype for premature local arteriosclerosis and atherosclerotic diseases in general.
In the present study, we showed the importance of traditional donor-related cardiovascular risk factors (age, diabetes mellitus and hypertension) in the development of severe allograft arteriosclerosis, which suggests that post-transplant accelerated arteriosclerosis may be partially donor-transmitted. We also demonstrated the relevance of traditional recipient risk factors including age, past history of MACE, diabetes mellitus, hypercholesterolemia, tobacco use and renal allograft function in the occurrence of posttransplant cardiovascular events.
Among the 174 studies addressing an association between antibodies and arteriosclerosis in the current literature, only three were prospective population-based studies evaluating anti-phosphorylcholine (38), anti-oxidized LDL (39) and anti-phospholipid (40) antibodies. None of these studies integrated the We defined a distinct disease entity, "antibody-associated arteriosclerosis," which is characterized by circulating donor-specific anti-HLA antibodies, prominent arterial intimal thickening and hypercellularity associated with allograft endothelial activation (microcirculation inflammation), and complement fraction C4d deposition. There is abundant experimental evidence for the pathophysiologic underpinnings of antibody-associated arteriosclerosis in animal models. Ligation of anti-class I and anticlass II antibodies on the vascular endothelium and smooth muscle cells induces the release of a variety of cytokines and stimulates the proliferation of myofibroblasts, inducing neointimal hyperplasia and transplant vasculopathy (6, 22, (41) (42) (43) . In the present human study, we found that both class I and II anti-HLA antibodies were associated with allograft arteriosclerosis. The severity of arteriosclerosis was correlated with increasing circulating DSA levels and their ability to bind complement. In addition, the severity of arteriosclerosis was correlated with a gradient of endothelial activation and complement allograft deposition. Our results suggested analogies with the heart transplant field in terms of an immune-mediated component in arteriosclerosis. Heart transplant recipients with late-onset allograft rejection develop accelerated chronic allograft vasculopathy (aka CAV, a fibrointimal thickening of epicardial coronary arteries), supporting a link between allo-antibodies and damage to large vessels (44) .
We demonstrate a robust and consistent association between circulating DSA and arteriosclerosis, which permits us to move further than simple associations, approaching causation by providing the following: i) the strength of the association between circulating DSA and the severity of arteriosclerosis; ii) a biological gradient: greater exposure to higher levels of circulating DSA (MFI level) and complementbinding capacity lead to higher incidence of severe arteriosclerosis; iii) temporality: the detection of circulating DSA in patient sera occurs before the assessment of arteriosclerosis; iv) independency with potential confounders: mathematic integration of traditional cardiovascular risk factors and adjustments to these parameters in robust epidemiological models showing strong and independent associations between circulating DSA and the severity of arteriosclerosis; v) biological plausibility of the hypothesis and the mechanism previously shown in small series (5, 6) and further supported by animal models showing that circulating anti-HLA antibodies induce an immune response involving endothelial activation and accompanying arteriosclerosis (21, 45); and vi) analogies with models of autoimmunity (lupus) with circulating auto-antibodies promoting the development of atherosclerosis and MACE (14) . Finally, the validation of the results in an independent cohort reinforces the robustness of the study and the exportability of our findings.
Notably, we show that circulating DSA is a strong determinant of MACE, independent of traditional cardiovascular risk factors. Our data support the notion that the severe arteriosclerosis observed in the allograft may be only a part of a more general vascular process operating in patients with circulating DSA. In the absence of direct access to patient arteries outside the allograft, this study cannot make conclusions regarding the mechanisms involved outside the allograft. A plausible hypothesis is that circulating DSA trigger allograft endothelial activation, endothelial injury, complement cascade activation and the release of cytokines and inflammatory mediators that extend to a more general vascular injury process (1, 11, 17, (46) (47) (48) . Local antibody-mediated injury may participate in a more systemic vascular injury process, demonstrating an interplay between immune activation and vascular remodeling. This process can lead to plaque progression and destabilization, as suggested by animal models and human studies of autoimmune disease (1, 17, 18, 46, 47, 49, 50) . This is also consistent with recent findings that establish a link between genetic susceptibility to coronary artery disease (e.g., 9p21 DNA variants) (51) and the altered responses of vascular cells to both inflammatory cytokines (e.g., Ifng) and proliferation/survival factors (47, 52, 53) .
Strengths and limitations.
The simultaneous evaluation of pre-and post-transplant immunological, histopathological and cardiovascular risk factors allowed us to address the multiple dimensions of arteriosclerosis development in renal allograft recipients. In particular, this unique approach permitted us to investigate the role of circulating anti-HLA antibodies, taking into account a large set of potentially confounding and mediating factors. However, we acknowledge that despite the robustness of our study findings, the study design did not permit us to provide a complete demonstration of causality between the presence of circulating anti-HLA antibodies, the development of arteriosclerosis, and the occurrence of MACE, and additional potential residual confounders may not have been taken into account in the assessment of these associations.
CONCLUSIONS
Using a multidisciplinary population-based approach, we demonstrate that circulating anti-HLA antibodies are major determinants of severe arteriosclerosis, independent of traditional cardiovascular risk factors. We also show that circulating anti-HLA antibodies exert long-term detrimental effects that are characterized by an increased risk of MACE. Thus, it is prudent to identify patients with circulating anti-HLA antibodies to screen them for cardiovascular diseases and aggressively treat traditional risk factors. Given the recent development of new immune-modulating agents, our study also opens avenues for the potential use of antibody targeting strategies in various human arterial diseases.
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Novelty and Significance
What Is Known?
 Traditional cardiovascular risk factors do not fully explain arteriosclerosis pathogenesis and its long-term clinical consequences.
 Experimental data suggest that immune processes play a role in arteriosclerosis.
 Past studies in humans did not aim to understand the contribution of immune determinants of arteriosclerosis beyond traditional cardiovascular risk factors.
 Kidney transplantation represents a unique human model where traditional cardiovascular risk factors co-exist with immune responses.
What New Information Does This Article Contribute?
 Circulating antibodies (anti-HLA) are major determinants of severe allograft arteriosclerosis, independent of traditional cardiovascular risk factors.
 Circulating antibodies are associated with an increased risk of cardiovascular events, independent of traditional cardiovascular risk factors.
Using a population-based approach in a large prospective cohort of kidney transplant recipients, we demonstrated that circulating antibodies (anti-HLA antibodies) are major risk factors for the development of arteriosclerosis and cardiovascular events, independent of traditional risk factors. We identified antibody-associated arteriosclerosis as an accelerated form of the disease, characterized by a distinct immunological and histological phenotype. High levels of circulating anti-HLA antibodies and their complement-binding capacity were associated with increased severity of arteriosclerosis and increased incidence of cardiovascular events. Circulating anti HLA-antibody levels were also associated with the major adverse clinical events independent of arteriosclerosis. Overall, our results support the notion of immunological development of arteriosclerosis in humans.
We identified a population of kidney transplant recipients at high risk of graft loss, major cardiovascular events and death, for whom specific screening and therapeutic strategies need to be developed. This idea extends beyond renal transplantation to reports of immunological damage to arteries in heart transplantations and other solid organs. The recognition of an immune component in the pathogenesis of severe arteriosclerosis could lead to the development of immune-modulating therapeutic strategies in solid organ transplant recipients and potentially in the general population. Subsequent maintenance immunosuppressive protocols consisted of prednisone, mycophenolate mofetil (1000 mg twice daily), tacrolimus (administered to maintain a target blood level of 8 to 10 ng per mL for the first 3 months and 6 to 8 ng per mL thereafter), or cyclosporine (administered to maintain a target C2 blood level of 800 to 1200 ng per mL for the first 3 months and 600 to 800 ng per mL thereafter).
Treatment of allograft rejection episodes
Patients with rejection episodes that were diagnosed as T-cell-mediated were treated with methylprednisolone pulses (500 mg/d for 3 days). 
SUPPLEMENTAL RESULTS
Research in context
We searched the PubMed database for reports in any language published before April 16, 2015 , with the search terms "cardiovascular risk factors", "arteriosclerosis" and "antibodies".
We identified 382 reports overall, of which 101 were reviews, 3 were letters, 2 were responses to letters, 1 was an editorial, 1 was a survey, 11 were studies in small animals, 8
were in vitro studies, 9 were case reports, 6 were randomized controlled trials and 240 were observational studies performed in humans; 57 studies addressed the association between antibodies and arteriosclerosis in autoimmune settings and 77 studies in infectious settings, 27 studies addressed the association between lipid-related antibodies and arteriosclerosis, 10 studies addressed the association between anti-heat shock protein antibodies and arteriosclerosis, 3 studies addressed the association between donor-specific anti-HLA antibodies and chronic allograft vasculopathy in heart allografts, and 66 studies addressed an association between various biomarkers/surrogate markers and arteriosclerosis.
Among the 174 studies addressing an association between antibodies and arteriosclerosis, we found 3 population-based prospective studies (anti-phosphorylcholine, anti-oxidized LDL and anti-phospholipid antibodies). None of these studies integrated the simultaneous assessment of circulating antibodies, arteries, traditional cardiovascular risk factors and clinical events.
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